The last point is that what the #OPTIMA trial hammered home is the we truly overprescribe chemotherapy (especially anthracycline based chemo) to ER breast cancer patients and in that molecularly low risk 40 patient population ovarian suppression and aromatase inhibitor is just as effective as chemo and less toxic. Our field needs to move towards de-escalating chemotherapy in ER disease (including premenopausal) and utilizing targeted therapy (ovarian suppression and aromatase inhibitors are some of the 1st targeted therapies). No more overuse of chemo in this population. It doesn't help!

📣COME JOIN this NEW innovative open discussion format, no didactics, just practice changing exchange. enjoy food/drinks & maybe win the raffle! Libretto 432 Harmoni 6 Crown Atypical EGFR ADC updates Tarla & more ⏱️ 6/10 wed 6-8:40 pm @mjeng21 @MSKCancerCenter @MSK_DeptOfMed

roche.com/media/releases/med… FDA expected to make decision on girdestrant in early stage BC by November 30, 2026!

So excited to share that my book is out on 9/29/2026!! Pre-order here a.co/d/0bdFkY8Q 🩷

From chemotherapy de-escalation and oral SERDs to metastatic triple-negative breast cancer and GLP-1 medicines, @drteplinsky breaks down some of the biggest breast cancer research updates from #ASCO26, what they could mean for breast cancer care, and the questions researchers are still working to answer. 🎧 Listen now: bit.ly/4dTmk9r #ASCO26 #BreastCancer #CancerResearch #BreastCancerWarrior

Practice-changing de-escalation data from REDUSE 96/12 at #ASCO2026. • Phase III non-inferiority trial (N=1380); 57% had metastatic breast cancer • Denosumab 120 mg Q12W after induction vs standard Q4W • Calcium 500 mg Vitamin D 400 IU daily mandated Key findings: • Q12W was non-inferior for prevention of symptomatic skeletal events (56.5 vs 56.6 months; HR 1.02) • Lower rates of hypocalcemia (HR 0.70) • ~25% reduction in ONJ • Swiss analysis showed a 53% reduction in costs, likely even greater in the US This study reinforces my current practice of extending denosumab dosing intervals. Less treatment, lower toxicity, lower cost, and no loss of efficacy. #BreastCancer #BoneMetastases #Denosumab #ASCO2026 @muschollings

#elizanetant improves not only vasomotor symptoms but also sleep for patients on all types (tamoxifen, AI, and GNRH ) endocrine therapy for #bcsm #ASCO26

Denosumab every 12 w after induction was non-inferior to every 4 w for skeletal-related events, with less hypocalcemia/ONJ and >50% reduction in drug costs. A great example of how smarter de-escalation can maintain efficacy while improving safety, convenience, and value for patients‼️ #ASCO2026 #bcsm @OncoAlert

Eleanor the hardworking @ASCO elephant had a busy day Sunday @ #asco26 - press conference, education session, CDK study investigator meeting, National Cancer Grid India discussion, exhibit hall & President’s reception. Phew! @cspramesh @ManjuSengar7 @LGM_Biostats @AbbyRosenbergMD

This speaks to a longer induction than 6-8 cycles…

One of my favorite slides from @stage4kelly’s @ASCO talk this a.m. Sadly unable to attend live, but watched the recording & delivering congrats, 🙌🏻 & standing 👏 from afar, my friend! Kelly did an outstanding job representing the #MBC community on the BIG stage, highlighting the importance of meaningful endpoints, transparent toxicity data, & including people with lived experience early in #clinicaltrial design. Patients aren’t just trial participants, & never “subjects,” but ultimate stakeholders. “Build a bigger table.” Exactly!🩷🩵💚 #ASCO26 #bcsm #PatientAdvocacy

Ending out #ASCO26 with a fantastic time at the President’s Reception!! @ARosen380 @msheenmd @JenSchwartzIUSM

Thank you @OncLive for a fantastic Women in Oncology event today!!! 📸 with some of the amazing women who attended! @mabelonc @DrReshmaMahtani @SaraNunneryMD @cancerfashion @DrKEMcCann @DrSAHaddad #ASCO26

As AI becomes increasingly integrated into cancer care, are patients being given the information they need to make informed decisions? Today at #ASCO26, @drteplinsky shared findings from a cross-sectional analysis exploring gaps in patient-facing information on AI in oncology and discusses the impact these gaps may have on trust, engagement, and participation in AI-informed care and clinical trials. @ASCO #AI #AIinOncology

Fresh data from #ASCO26 shows a massive blind spot: online resources about AI in cancer care are largely low-quality & completely omit the risks of AI hallucination & misinformation. We need a major push for AI literacy to protect patients! 🛑🤖 #OncTwitter #CancerCare #meded

@drteplinsky Great conclusion ‼️ 🤔 What are we doing to avoid this? #ASCO26 #digitalhealth #AAOCDigital

Come to our session - Oncology 2.0: How Artificial Intelligence Is Closing the Information Gap—Or Is It? Starting 9:45 CST, S102! -going to be a great discussion! @MatthewKurianMD #ASCO26

#ASCO2026 is off to a great start! I was honored to chair this session: “Optimizing Breast Cancer Survivorship: Addressing Lifestyle, Weight Management, and Psychological Health.”It was wonderful to speak alongside experts Sophie Lebel,PhD, @SherryShenMD, & @LauraCarfang. #bcsm

#asco26. Key data from the exciting LidERA study in premenop pts presented by Schmid. Benefit x menopausal status & most Rx with tam in control received LHRHa. Less d/c due to pain. Longer FU needed for medium risk. Q - combo with CDK4/6i or instead? More data T/F @OncoAlert

🔑 Take aways from @ASCOPres address “If a pt cannot get the treatment they need or cannot make it to the center to get care, it’s a unmet promise. How can we keep our promise?” “Toxicity is acceptable , ONLY if it’s acceptable to the pt”, YES TO THIS 🙌🏽